Menu Search
Equities

Navamedic ASA

NAVA:OSL

Navamedic ASA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (NOK)25.10
  • Today's Change-0.80 / -3.09%
  • Shares traded4.83k
  • 1 Year change-31.42%
  • Beta--
Data delayed at least 15 minutes, as of Nov 25 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in NOKIncome statement in NOKView more

Year on year Navamedic ASA had net income fall -88.77% from 29.43m to 3.30m despite a 33.98% increase in revenues from 382.14m to 512.00m. An increase in the selling, general and administrative costs as a percentage of sales from 12.58% to 22.44% was a component in the falling net income despite rising revenues.
Gross margin40.04%
Net profit margin4.53%
Operating margin8.74%
Return on assets4.91%
Return on equity10.82%
Return on investment7.35%
More ▼

Cash flow in NOKView more

In 2023, cash reserves at Navamedic ASA fell by 17.26m. Cash Flow from Financing totalled 83.24m or 16.26% of revenues. In addition the company generated 2.18m in cash from operations while cash used for investing totalled 104.58m.
Cash flow per share2.29
Price/Cash flow per share11.48
Book value per share14.00
Tangible book value per share-0.2043
More ▼

Balance sheet in NOKView more

Navamedic ASA has a Debt to Total Capital ratio of 36.86%, a lower figure than the previous year's 51.23%.
Current ratio1.44
Quick ratio0.8753
Total debt/total equity0.5837
Total debt/total capital0.3686
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.